TABLE 2.
Susceptibility profiles of the bacterial strains included in this studya
| Strain | MIC (μg/ml) (susceptibility rating) for indicated drug
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TGC | MIN | GEN | TOB | CIP | CHL | PIP | CAZ | FEP | IPM | MEM | |
| D54 | 0.125 | 0.125 (S) | 0.25 (S) | 0.75 (S) | 0.25 (S) | 0.125 (S) | 16 (S) | 4.0 (S) | 1.5 (S) | 0.125 (S) | 0.25 (S) |
| A24 | 2.0 | 32 (R) | 64 (R) | 4.0 (S) | 256 (R) | 16 (I) | 16 (S) | >256 (R) | 16 (I) | 0.38 (S) | 1.0 (S) |
| A24 + PABN | 2.0 | 2.0 (S) | 48 (R) | 3.0 (S) | 128 (R) | 12 (I) | 3.0 (S) | 96 (R) | 3.0 (S) | 0.032 (S) | 0.094 (S) |
| A24A | 2.0 | 12 (I) | 256 (R) | 3.0 (S) | 256 (R) | 96 (R) | 12 (S) | >256 (R) | 12 (I) | 0.125 (S) | 0.75 (S) |
| A24B | 2.0 | 16 (R) | 256 (R) | 4.0 (S) | 256 (R) | 96 (R) | 12 (S) | >256 (R) | 12 (I) | 0.125 (S) | 0.75 (S) |
| A24C | 6.0 | 16 (R) | 512 (R) | 6.0 (I) | 256 (R) | 96 (R) | 16 (S) | >256 (R) | 16 (I) | 0.19 (S) | 0.75 (S) |
| A24Db | 24 | 32 (R) | 256 (R) | 16 (R) | 512 (R) | 16 (I) | 24 (I) | >256 (R) | 16 (I) | 0.50 (S) | 2.0 (S) |
| A24D + PABN | 2.0 | 8.0 (I) | 96 (R) | 8.0 (I) | 128 (R) | 4.0 (S) | 1.0 (S) | 32 (R) | 1.0 (S) | 0.064 (S) | 0.094 (S) |
| B46 | 4.0 | 0.25 (S) | 8.0 (I) | 24 (R) | 128 (R) | 32 (R) | 256 (R) | 96 (R) | >256 (R) | 1.5 (S) | 4.0 (I) |
| B46 + PABN | 1.0 | 0.25 (S) | 4.0 (S) | 16 (R) | 128 (R) | 8.0 (S) | 256 (R) | 8.0 (S) | 128 (R) | 0.25 (S) | 0.25 (S) |
| C75 | 16 | 2.0 (S) | 128 (R) | 16 (R) | 512 (R) | 32 (R) | 48 (I) | 192 (R) | >256 (R) | 1.5 (S) | 4.0 (I) |
| C75 + PABN | 4.0 | 1.0 (S) | 16 (R) | 6.0 (I) | 256 (R) | 8.0 (S) | 8.0 (S) | 8.0 (S) | 16 (I) | 0.125 (S) | 0.125 (S) |
a
TGC, tigecycline; MIN, minocycline; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; CHL, chloramphenicol; PIP, piperacillin; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem; R, resistant; S, susceptible; I, intermediate.
b
An isolate that underwent tigecycline in vitro exposure.